Biosciences

medicine

What I’m doing now: from Biomedical Science to Medicine | Biosciences at Sheffield

Mélina Li How Cheong student profile

I graduated from the Biomedical Science course at the university of Sheffield back in 2015 and am now in my 2nd year of Medicine at the University of Buckingham.

I know of a few graduates from my Sheffield cohort that are now also studying to become a doctor and similarly, there are quite a few other people on my medical course who have also already completed an undergraduate degree. In comparison to other biomedical science courses, I believe that Sheffield has given me a significant advantage in preparing me for my degree in medicine.

At the end of secondary school, I had initially applied to the University of Sheffield for medicine. Unfortunately I did not get in, but the university was willing to accept me for the biomedical science course.

This ended up being very beneficial in preparing me for my future studies in medicine. I really enjoyed the course because I thought that there was a good balance between molecular biology and physiology. Additionally, the lecturers often made sure to relate the lecture contents to how they applied in clinical medicine and in real life.

When starting the medical course, I quickly noticed that I had a strong foundation in human physiology compared to my fellow students. It seemed that a lot of other biomedical courses were more heavily focused on the molecular and cellular aspect of biology.

Another key advantage that the biomedical science course at Sheffield offered me was the anatomy module, which was by far my favourite part of the course.


Even though I had not studied anatomy for over 2 years before starting it in medical school, everything came back to me very quickly and made that part of the course very easy for me

Mélina Li How Cheong

BSc Biomedical Science


In second and third year, we got to do dissections on cadavers, an invaluable experience as not all universities can offer this. Even a lot of medical schools nowadays do not have the facilities to offer dissections as part of their anatomy course.

The quality of teaching was of a very high standard which gave me a thorough understanding of human anatomy. Therefore, even though I had not studied anatomy for over 2 years before starting it in medical school, everything came back to me very quickly and made that part of the course very easy for me.

Additionally, after graduating, I had the opportunity to work as an Anatomy Demonstrator for a semester at the University of Sheffield, which gave me valuable work experience in teaching, as well as allowing me to further consolidate my knowledge of human anatomy.

Soon I will be starting my clinical rotations. I do not yet know what specialty I will be going into as I want to keep an open mind and explore as I work in different departments. One thing I do know is that I want to get involved in teaching at some point in my career.

It is through my experience as an

Read More
medicine

Foundation Medicine Enters into Patent Licensing and Technology Agreement with TwinStrand Biosciences

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine today announced it has entered into a non-exclusive agreement to license two foundational patent families from TwinStrand Biosciences, a next-generation DNA sequencing technology company based in Seattle.

The patented TwinStrand Duplex Sequencing™ technology is a biochemistry- and software-based platform that enables researchers and clinicians to detect faint signals of ultra-low frequency DNA mutations often obscured by technical noise.

“Advancing and improving patient care is our highest priority and we’re pleased to work with partners like TwinStrand who share this same goal,” said Cindy Perettie, Foundation Medicine’s chief executive officer. “We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration.”

“We are delighted to partner with Foundation Medicine, a company that shares our patient-centric mission of applying innovative science to advance cancer care globally,” said Jesse Salk, MD, PhD, TwinStrand’s chief executive officer. “We are excited to help power Foundation Medicine’s commitment to delivering the highest quality data and genomic insights to physicians and their patients.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

About TwinStrand Biosciences

TwinStrand Biosciences is leading the way in identifying rare genetic variants that are undetectable by standard sequencing methods. The company’s highly-sensitive and specific Duplex Sequencing™ technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, where actions are most impactful. TwinStrand’s scientist-leaders have authored more than a dozen peer-reviewed articles using Duplex Sequencing and have developed a portfolio of more than 70 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.TwinStrandBio.com.

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

Source Article

Read More
medicine

TwinStrand Biosciences Licenses Duplex Sequencing Technology to Foundation Medicine

SEATTLE, Nov. 18, 2020 /PRNewswire/ — TwinStrand Biosciences today announced it has entered into a worldwide non-exclusive agreement to sublicense two foundational patent families to Foundation Medicine and its affiliates relating to TwinStrand Duplex Sequencing™ error-correction technology. Duplex Sequencing increases the accuracy of next-generation sequencing as much as 10,000 times, allowing the detection of ultra-low frequency mutations that would otherwise be hidden by technical noise inherent to the sequencing process.

“Staying at the forefront of innovative solutions to advance cancer care is central to our commitment to patients,” said Cindy Perettie, chief executive officer at Foundation Medicine. “We are excited to partner with TwinStrand to support doctors in making genomically-informed treatment decisions.”

“This agreement validates the strength of TwinStrand’s technology and intellectual property portfolio,” said Dr. Jesse Salk, chief executive officer at TwinStrand Biosciences. “We are pleased that Foundation Medicine has partnered with us to use our patented technology to achieve the highest possible performance for liquid biopsy testing.”

About TwinStrand Biosciences
TwinStrand Biosciences is leading the way in identifying rare genetic variants that are undetectable by standard sequencing methods. The company’s highly-sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, where actions are most impactful. TwinStrand’s scientist-leaders have authored more than a dozen peer-reviewed articles using Duplex Sequencing and have developed a portfolio of more than 70 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.twinstrandbio.com.

About Foundation Medicine
Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG). Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Media Contact:
[email protected]

SOURCE TwinStrand Biosciences

Related Links

http://www.twinstrandbio.com

Source Article

Read More
medicine

Foundation Medicine Enters into Patent Licensing and Technology Agreement with TwinStrand Biosciences – Press Release

CAMBRIDGE, Mass.–(Business Wire)–Foundation Medicine today announced it has entered into a non-exclusive agreement to license two foundational patent families from TwinStrand Biosciences, a next-generation DNA sequencing technology company based in Seattle.

The patented TwinStrand Duplex Sequencing™ technology is a biochemistry- and software-based platform that enables researchers and clinicians to detect faint signals of ultra-low frequency DNA mutations often obscured by technical noise.

“Advancing and improving patient care is our highest priority and we’re pleased to work with partners like TwinStrand who share this same goal,” said Cindy Perettie, Foundation Medicine’s chief executive officer. “We look forward to expanding this agreement with TwinStrand to explore additional areas for future collaboration.”

“We are delighted to partner with Foundation Medicine, a company that shares our patient-centric mission of applying innovative science to advance cancer care globally,” said Jesse Salk, MD, PhD, TwinStrand’s chief executive officer. “We are excited to help power Foundation Medicine’s commitment to delivering the highest quality data and genomic insights to physicians and their patients.”

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company offers a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

About TwinStrand Biosciences

TwinStrand Biosciences is leading the way in identifying rare genetic variants that are undetectable by standard sequencing methods. The company’s highly-sensitive and specific Duplex Sequencing™ technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health and other fields of science on a faster timescale, where actions are most impactful. TwinStrand’s scientist-leaders have authored more than a dozen peer-reviewed articles using Duplex Sequencing and have developed a portfolio of more than 70 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. For more information visit www.TwinStrandBio.com.

Foundation Medicine® is a registered trademark of Foundation Medicine, Inc.

Source: Foundation Medicine

Lee-Ann Murphy, 617-245-3077

[email protected]

Abigail Alderman, 781-534-3210

[email protected]

// Load the SDK Asynchronously (function(d){ var js, id = 'facebook-jssdk', ref = d.getElementsByTagName('script')[0]; if (d.getElementById(id)) {return;} js = d.createElement('script'); js.id = id; js.async = true; js.src = "http://connect.facebook.net/en_US/all.js"; ref.parentNode.insertBefore(js, ref); })(document); })();

Source Article

Read More